Plasma Chemerin may predict Type-2 Diabetes Remission after Bariatric Surgery

Abstract

Angel Alfonso Garduno-Perez, Jesus Montoya-Ramirez, Gustavo De La Pena-Sosa, Karen De La Vega- Moreno, Dulce Cecilia Vazquez-Ramos, Andrea Ramirez-Coyotecatl, Eduardo Vera-Gomez, Alejandro Hernandez-Patricio, Carlos Ramiro Zamora-Aleman, Silvia Garcia3 and Juan Antonio Suarez-Cuenca*

Bariatric surgery is an effective treatment for patients with severe obesity and type 2 diabetes mellitus (T2DM), leading to significant metabolic improvement and diabetes remission in a substantial proportion of cases. However, remission is not universal, and biological factors influencing postoperative metabolic response remain incompletely characterized. Adipokines such as chemerin and visfatin have been implicated in insulin resistance and adipose tissue inflammation and may contribute to heterogeneous outcomes after surgery.

Aim: To evaluate metabolic changes associated with T2DM remission after bariatric surgery and to assess the relationship between preoperative circulating adipokines and diabetes remission.

Methods: Prospective observational cohort study of 30 adults with T2DM and severe obesity undergoing bariatric surgery. Clinical, anthropometric, and biochemical variables were assessed at baseline and at 6 months postoperatively. Patients were classified according to complete T2DM remission status.

Results : At 6 months, 14 patients (46%) achieved complete T2DM remission. Remission was associated with significant reductions in fasting glucose and HbA1c, increased HDL-cholesterol, and reduced triglycerides. Higher preoperative chemerin levels were associated with lack of remission, while visfatin showed no significant association.

Conclusions: Elevated preoperative chemerin levels may identify patients at risk of persistent T2DM after bariatric surgery.

HTML PDF